Rocket Pharmaceuticals (RCKT) Free Cash Flow (2014 - 2026)

Rocket Pharmaceuticals has disclosed Free Cash Flow across 13 years of filings, most recently posting -$45.4 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$45.4 million, up 18.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$180.0 million (up 15.31% YoY), and the FY2025 annual result was -$190.5 million, up 11.66% from the prior year.
• Free Cash Flow came in at -$45.4 million for Q1 2026 at Rocket Pharmaceuticals, down from -$35.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$34.0 million in Q4 2023 to a low of -$67.7 million in Q3 2023.
• The 5-year median for Free Cash Flow is -$49.3 million (2025), against an average of -$49.6 million.
• Across the five-year window, Free Cash Flow slumped 67.32% in 2022 and jumped 35.58% in 2023, its largest moves.
• Rocket Pharmaceuticals' Free Cash Flow stood at -$52.8 million in 2022, then jumped by 35.58% to -$34.0 million in 2023, then plunged by 39.03% to -$47.3 million in 2024, then gained by 25.33% to -$35.3 million in 2025, then declined by 28.67% to -$45.4 million in 2026.
• The last three Free Cash Flow figures came in at -$45.4 million (Q1 2026), -$35.3 million (Q4 2025), and -$50.0 million (Q3 2025), per Business Quant data.